Sulindac Sulfide Is a Noncompetitive γ-Secretase Inhibitor That Preferentially Reduces Aβ42 Generation*

@article{Takahashi2003SulindacSI,
  title={Sulindac Sulfide Is a Noncompetitive $\gamma$-Secretase Inhibitor That Preferentially Reduces A$\beta$42 Generation*},
  author={Yasuko Takahashi and I. Hayashi and Yusuke Tominari and K. Rikimaru and Y. Morohashi and T. Kan and H. Natsugari and T. Fukuyama and T. Tomita and T. Iwatsubo},
  journal={The Journal of Biological Chemistry},
  year={2003},
  volume={278},
  pages={18664 - 18670}
}
Nonsteroidal anti-inflammatory drugs (NSAIDs) have been known to reduce risk for Alzheimer's disease. In addition to the anti-inflammatory effects of NSAIDs to block cylooxygenase, it has been shown recently that a subset of NSAIDs selectively inhibits the secretion of highly amyloidogenic Aβ42 from cultured cells, although the molecular target(s) of NSAIDs in reducing the activity of γ-secretase for Aβ42 generation (γ42-secretase) still remain unknown. Here we show that sulindac sulfide (SSide… Expand

Figures from this paper

Evidence That Nonsteroidal Anti-inflammatory Drugs Decrease Amyloid β42 Production by Direct Modulation of γ-Secretase Activity*
Chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with a lower risk of developing Alzheimer's disease. Recent evidence indicates that some NSAIDs specifically inhibitExpand
Selected Non-steroidal Anti-inflammatory Drugs and Their Derivatives Target γ-Secretase at a Novel Site
TLDR
It is demonstrated that in cell-free systems the mode of action of selected NSAIDs and their derivatives, depending on the concentrations used, can either be classified as modulatory or inhibitory. Expand
γ-Secretase Modulation with Aβ42-Lowering Nonsteroidal Anti-Inflammatory Drugs and Derived Compounds
The amyloid-β (Aβ) peptides and specifically the highly amyloidogenic isoform Aβ42 appear to be key agents in the pathogenesis of familial and sporadic forms of Alzheimer’s disease (AD). The finalExpand
Insensitivity to Aβ42-lowering Nonsteroidal Anti-inflammatory Drugs and γ-Secretase Inhibitors Is Common among Aggressive Presenilin-1 Mutations*♦
TLDR
Genetic dissection of the PS1-ΔExon9 mutation is demonstrated to demonstrate that a synergistic effect of the S290C mutation and the lack of endoproteolytic cleavage is sufficient to elevate the Aβ42/Aβ40 ratio and that the attenuated response to sulindac sulfide results partially from the deficiency in endoproteinolysis. Expand
Presenilin Is the Molecular Target of Acidic γ-Secretase Modulators in Living Cells
TLDR
It is demonstrated that potent acidic GSMs target presenilin to modulate the enzymatic activity of the γ-secretase complex, which is a principal therapeutic target in Alzheimer's disease. Expand
Aβ42-lowering Nonsteroidal Anti-inflammatory Drugs Preserve Intramembrane Cleavage of the Amyloid Precursor Protein (APP) and ErbB-4 Receptor and Signaling through the APP Intracellular Domain*
TLDR
It is demonstrated that S3-like/intramembrane cleavage is preserved by Aβ42-lowering NSAIDs in at least three substrates of γ-secretase APP, ErbB-4, and NOTCH and underline the striking specificity by which these drugs target A β42 production. Expand
Therapeutic Potential of γ -Secretase Inhibitors and Modulators
TLDR
Clinical studies with other potent  -secretase inhibitors will tell us if these pharmacodynamic and tolerability profiles observed in humans are typical of the pharmacological class or are compound-specific. Expand
Pharmacological characterization of the novel γ-secretase modulator AS2715348, a potential therapy for Alzheimer's disease, in rodents and nonhuman primates
TLDR
The promise for AS2715348 is shown as a potential disease-modifying drug for Alzheimer's disease after it was seen to reduce both cell-free and cellular production of Aβ42 without increasing levels of APP β-carboxyl terminal fragment or inhibiting Notch signaling. Expand
Development and mechanism of γ-secretase modulators for Alzheimer's disease.
TLDR
The findings call for the development of disease-modifying agents that target γ-secretase activity to lower levels of Aβ42 production without blocking the overall processing ofγ- secretase substrates. Expand
Allosteric regulation of γ-secretase activity by a phenylimidazole-type γ-secretase modulator
TLDR
A model for the mechanism of action of the phenylimidazole-type GSM in which binding at the luminal side of PS induces a conformational change in the catalytic center of γ-secretase to modulate Aβ production is provided. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 44 REFERENCES
Linear Non-competitive Inhibition of Solubilized Human γ-Secretase by Pepstatin A Methylester, L685458, Sulfonamides, and Benzodiazepines*
TLDR
It is reported that pepstatin A methylester and L685458 unexpectedly displayed linear non-competitive inhibition of γ-secretase, and Sulfonamides and benzodiazepines, which do not resemble transition state analogs of aspartyl proteases, also displayed potent, non- competitive inhibition ofγ- secretase. Expand
A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity
TLDR
It is reported that the NSAIDs ibuprofen, indomethacin and sulindac sulphide preferentially decrease the highly amyloidogenic Aβ42 peptide (the 42-residue isoform of the amyloids-β peptide) produced from a variety of cultured cells by as much as 80%. Expand
Presenilin-1 and -2 Are Molecular Targets for γ-Secretase Inhibitors*
TLDR
Results indicate that potent and selective γ-secretase inhibitors block Aβ formation by binding to presenilin-1 and -2, and a benzophenone analog specifically photocross-links three major membrane polypeptides. Expand
Rank-Order of Potencies for Inhibition of the Secretion of Aβ40 and Aβ42 Suggests That Both Are Generated by a Single γ-Secretase*
TLDR
The hypothesis that Aβ variants ending at residue 40 or 42 are generated by a single γ-secretase is supported, as IC50 values for inhibition of Aβ42 and Aβ40 were found to have the same rank-order and fall on a trend line with near-unit slope. Expand
Amyloid-lowering isocoumarins are not direct inhibitors of γ-secretase
To the Editor — Recent reports have described the interaction of specific phosphoinositides (PIs) with the phox homology (PX) domain of several proteins, including the phagocyte NADPH oxidaseExpand
Photoactivated γ-secretase inhibitors directed to the active site covalently label presenilin 1
Cleavage of amyloid precursor protein (APP) by the β- and γ-secretases generates the amino and carboxy termini, respectively, of the Aβ amyloidogenic peptides Aβ40 and Aβ42—the major constituents ofExpand
Presenilin-dependent γ-secretase activity modulates thymocyte development
TLDR
It is shown that high concentrations of the most potent inhibitors blocked thymocyte development at the most immature stage, and lower concentrations or less potent inhibitors impaired differentiation at a later stage, most notably suppressing the development of CD8 single-positive T cells. Expand
New protease inhibitors prevent γ-secretase-mediated production of Aβ40/42 without affecting Notch cleavage
TLDR
These represent the first non-peptidic inhibitors that are able to prevent γ-secretase cleavage of βAPP without affecting processing of mΔEnotch-1 or endoproteolysis of presenilins. Expand
Selective inhibition of Aβ42 production by NSAID R‐enantiomers
Non‐steroidal anti‐inflammatory drugs (NSAIDs) have been associated with reduced risk for Alzheimer's disease (AD) and selected NSAIDs racemates suppress β‐amyloid (Aβ) accumulation in vivo and Aβ42Expand
Activity-dependent isolation of the presenilin– γ-secretase complex reveals nicastrin and a γ substrate
TLDR
Results provide direct biochemical evidence that nicastrin is a member of the active γ-secretase complex, indicate that β-catenin, calsenilin, and presenil in-associated protein are not required for γ activity, and suggest an unprecedented mechanism of substrate–protease interaction. Expand
...
1
2
3
4
5
...